A Phase I Study of 5-Azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma
Drugs used in chemotherapy, such as azacitidine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interferon alfa-2b may interfere with the growth of tumor cells. Giving azacitadine together
with interferon alfa-2b may kill more tumor cells.
This phase I trial is studying the side effects and best dose of interferon alfa-2b
when given together with azacitidine in treating patients with stage III or stage IV
melanoma or stage IV kidney cancer that cannot be removed by surgery.
Study Status: Active, not recruiting
Biological: recombinant interferon alfa-2b
Information provided by:
National Cancer Institute (NCI)
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
Mario Sznol, MD., Study Chair